Literature DB >> 11038159

Decreased in vivo metabolism of drugs in chronic renal failure.

F A Leblond1, L Giroux, J P Villeneuve, V Pichette.   

Abstract

Chronic renal failure (CRF) is associated with a decrease in renal excretion of drugs, but its effects on the liver metabolism of xenobiotics are poorly defined. The objectives of this study were to determine the effects of CRF on hepatic cytochrome P450 (CYP450) and its repercussions on in vivo hepatic metabolism of drugs. Two groups of rats were studied: control paired-fed and CRF. CRF was induced by subtotal nephrectomy. Total CYP450 activity and protein expression of several CYP450 isoforms (CYP1A2, CYP2C11, CYP3A1, CYP3A2) were assessed in liver microsomes. In vivo cytochrome P450 activity was evaluated with breath tests using substrates for different isoenzymes: caffeine (CYP1A2), aminopyrine (CYP2C11), and erythromycin (CYP3A2). Creatinine clearance was reduced by 60% (P <. 01) in rats with CRF. Compared with control paired-fed rats, total CYP450 activity was reduced by 40% in rats with CRF. Protein expression of CYP2C11, CYP3A1, and CYP3A2 was considerably reduced (more than 45%, P <.001) in rats with CRF, whereas the levels of CYP1A2 were unchanged. In rats with CRF, there was a 35% reduction in the aminopyrine (CYP2C11) and the erythromycin (CYP3A2) breath tests compared with control animals (P <.001). The caffeine (CYP1A2) breath tests remained comparable to controls. Creatinine clearance correlated with the aminopyrine and erythromycin breath tests (r(2) = 0.73 and r(2) = 0.81, respectively, P <.001). In conclusion, CRF is associated with a decrease in total liver CYP450 activity in rats (mainly in CYP2C11, CYP3A1, and CYP3A2), which leads to a significant decrease in the metabolism of drugs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11038159

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  30 in total

1.  Downregulation of hepatic acetylation of drugs in chronic renal failure.

Authors:  Emilie Simard; Judith Naud; Josée Michaud; Francois A Leblond; Alain Bonnardeaux; Chantal Guillemette; Edith Sim; Vincent Pichette
Journal:  J Am Soc Nephrol       Date:  2008-04-16       Impact factor: 10.121

2.  Integrative biology identifies shared transcriptional networks in CKD.

Authors:  Sebastian Martini; Viji Nair; Benjamin J Keller; Felix Eichinger; Jennifer J Hawkins; Ann Randolph; Carsten A Böger; Crystal A Gadegbeku; Caroline S Fox; Clemens D Cohen; Matthias Kretzler
Journal:  J Am Soc Nephrol       Date:  2014-06-12       Impact factor: 10.121

Review 3.  Consequences of renal failure on non-renal clearance of drugs.

Authors:  Laure Lalande; Bruno Charpiat; Gilles Leboucher; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447

Review 4.  Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives.

Authors:  Flavia Storelli; Caroline Samer; Jean-Luc Reny; Jules Desmeules; Youssef Daali
Journal:  Clin Pharmacokinet       Date:  2018-10       Impact factor: 6.447

5.  Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group.

Authors:  Melanie S Joy; Debbie S Gipson; Mary Dike; Leslie Powell; Amber Thompson; Suzanne Vento; Allison Eddy; Agnes B Fogo; Jeffrey B Kopp; Daniel Cattran; Howard Trachtman
Journal:  Clin J Am Soc Nephrol       Date:  2008-12-10       Impact factor: 8.237

6.  Pharmacokinetic and pharmacodynamic profile of rosuvastatin in patients with end-stage renal disease on chronic haemodialysis.

Authors:  Bruce K Birmingham; Suzanne K Swan; Tom Puchalski; Pat Mitchell; Connie Azumaya; Julie Zalikowski; Yi Wang
Journal:  Clin Drug Investig       Date:  2013-04       Impact factor: 2.859

7.  The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis.

Authors:  Samir K Gupta; Susan L Rosenkranz; Yoninah S Cramer; Susan L Koletar; Lynda A Szczech; Valerianna Amorosa; Stephen D Hall
Journal:  AIDS       Date:  2008-10-01       Impact factor: 4.177

8.  Decreased lithium disposition to cerebrospinal fluid in rats with glycerol-induced acute renal failure.

Authors:  Rie Sakae; Atsuko Ishikawa; Tomoko Niso; Yukiko Komori; Tetsuya Aiba; Hiromu Kawasaki; Yuji Kurosaki
Journal:  Pharm Res       Date:  2008-06-26       Impact factor: 4.200

9.  Effect of severe renal impairment on the pharmacokinetics of azimilide following single dose oral administration.

Authors:  Alfred E Corey; Jeffrey R Agnew; Suzanne N Valentine; Nikhil J Parekh; James H Powell; Gary A Thompson
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

10.  Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease.

Authors:  H Sun; L A Frassetto; Y Huang; L Z Benet
Journal:  Clin Pharmacol Ther       Date:  2010-01-20       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.